Riken Vitamin Co., Ltd.
Notice Regarding Revision of the Medium-Term Management Plan 2027
Resolution to revise the Medium-Term Management Plan 2027. Reduce the proportion of low-margin commodity products in overseas operations and shift to specialty products; review the production system at Rikevita Malaysia. Numerical targets for the fiscal year ending March 2028 have been revised and the dividend policy will also be reviewed.
Key Figures
- Net Sales: 1,050 hundred million yen (revised)
- Operating Income: 80 hundred million yen (revised)
- EBITDA: 122 hundred million yen (revised)
AI要約
Background and Policy for Revising the Medium-Term Plan
The Company resolved to revise the Medium-Term Management Plan 2027. To respond to structural changes in overseas markets, the Group will reduce the proportion of low-margin commodity products and accelerate the shift to specialty products. The Company will review the production system at its largest overseas manufacturing site, Rikevita Malaysia. Accordingly, management targets and measures under the plan will be reassessed, and the dividend policy will also be reviewed.
Numerical Targets and Dividend Policy for the Fiscal Year Ending March 2028
Revised numerical targets are net sales of 1,050 hundred million yen, operating income of 80 hundred million yen, EBITDA of 122 hundred million yen, ROE of 10%, and an increase in the shareholders' equity ratio to approximately 70%. The dividend policy has been revised. For details of the revised dividend policy and adjustments to dividend forecasts (increase), refer to the separate notice titled "Notice Regarding Change in Dividend Policy and Revision of Dividend Forecast (Dividend Increase)".
Riken Vitamin Co., Ltd.
Company overview · Stock price · Financial data · All IR
